|Specificity:||The mouse monoclonal antibody 24-31 detects CD154 / CD40L (CD40-ligand), a 39 kDa cell surface type II glycoprotein expressed predominantly on activated CD4+ lymphocytes.|
|Immunogen:||human CD154 fusion protein|
|Species Reactivity:||Human, Non-Human Primates|
|Preparation:||The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.|
|Storage Buffer:||The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.|
|Storage / Stability:||Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.|
|Usage:||The reagent is designed for Flow Cytometry analysis of human blood cells using 10 μl reagent / 100 μl of whole blood or 106 cells in a suspension.
The content of a vial (0.25 ml) is sufficient for 25 tests.
|Expiration:||See vial label|
|Lot Number:||See vial label|
|Background:||CD154 / CD40L (CD40 ligand) is a member of the tumor necrosis factor family, and is expressed primarily on activated CD4+ lymphocytes, but also on mast cells, basophils, eosinophils and human dendritic cells. Its counter-receptor CD40 is expressed on antigen presenting cells, including dendritic cells, macrophages, and B cells, and also on fibroblasts. Triggering of CD40 by CD40L causes maturation of dendritic cells and upregulation of antigen presentation in functions of the MHC and costimulatory molecules. CD40L also functions as a direct stimulating factor for T cells. CD40L plays also roles e.g. in antibody class switching and modulation of apoptosis in the germinal center.|
*Kum WW, Hung RW, Cameron SB, Chow AW: Temporal sequence and functional implications of V beta-specific T cell receptor down-regulation and costimulatory molecule expression following in vitro stimulation with the staphylococcal superantigen Toxic shock syndrome toxin-1. J Infect Dis. 2002 Feb 15;185(4):555-60
*Fernandes MS, Gomes EM, Butcher LD, Hernandez-Alcoceba R, Chang D, Kansopon J, Newman J, Stone MJ, Tong AW: Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clin Cancer Res. 2009 Aug 1;15(15):4847-56.
*Barnhart B, Ford GS, Bhushan A, Song C, Covey LR: A polymorphic CD40 ligand (CD154) molecule mediates CD40-dependent signalling but interferes with the ability of soluble CD40 to functionally block CD154:CD40 interactions. Immunology. 2000 Jan;99(1):54-61.
*Grammer AC, McFarland RD, Heaney J, Darnell BF, Lipsky PE: Expression, regulation, and function of B cell-expressed CD154 in germinal centers. J Immunol. 1999 Oct 15;163(8):4150-9.
*Kornbluth RS, Kee K, Richman DD: CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5205-10.
*Berner B, Wolf G, Hummel KM, Müller GA, Reuss-Borst MA: Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis. Ann Rheum Dis. 2000 Mar;59(3):190-5.
*Brams P, Black A, Padlan EA, Hariharan K, Leonard J, Chambers-Slater K, Noelle RJ, Newman R: A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation. Int Immunopharmacol. 2001 Feb;1(2):277-94.
For laboratory research only, not for drug, diagnostic or other use.
EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic